Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF HMG-CoA REDUCTASE INHIBITOR FOR TREATING CISPLATIN-RESISTANT CANCERS
Document Type and Number:
WIPO Patent Application WO/2014/119568
Kind Code:
A1
Abstract:
The present invention provides a means for treating cisplatin-resistant cancers. Specifically, the present invention provides a cisplatin-resistant cancer cytotoxic agent or the like, which contains an HMG-CoA reductase inhibitor. The present invention enables cisplatin-resistant cancers to be effectively destroyed, thereby enabling cisplatin-resistant cancers to be treated.

Inventors:
KOHNO KIMITOSHI (JP)
IZUMI HIROTO (JP)
Application Number:
PCT/JP2014/051833
Publication Date:
August 07, 2014
Filing Date:
January 28, 2014
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV OCCUPATIONAL AND ENVIRONMENTAL HEALTH JAPAN (JP)
International Classes:
A61K45/00; A61K31/22; A61K31/366; A61K31/40; A61K31/404; A61K31/47; A61P15/00; A61P35/00
Other References:
TAMARA CIMBORA-ZOVKO ET AL.: "Determinants of Increased Sensitivity to Lovastatin-induced Apoptosis in Cisplatin-resistant Human Laryngeal Carcinoma Cells", DRUG METABOLISM REVIEWS, vol. 41, no. 1, 2009, pages 65 - 66
OSMAK M. ET AL.: "Mechanisms involved in increased sensitivity of cisplatin resistant human laryngeal carcinoma cells to lovastatin", EUROPEAN JOURNAL OF CANCER, vol. 7, no. 2-3, 2009, pages 94 - 95
ENGELKE K.J. ET AL.: "A non-characteristic response of L1210 cells to lovastatin.", BIOCHEM BIOPHYS RES COMMUN, vol. 203, no. 1, 1994, pages 400 - 407
Attorney, Agent or Firm:
TAKASHIMA, HAJIME (JP)
Takashima 1 (JP)
Download PDF: